Cita APA

Cella, D., Grünwald, V., Escudier, B., Hammers, H. J., George, S., Nathan, P., . . . Motzer, R. J. (2019). Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): A randomised, phase 3 trial. Lancet Oncol.

Chicago Style Citation

Cella, David, et al. "Patient-reported Outcomes of Patients With Advanced Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab Versus Sunitinib (CheckMate 214): A Randomised, Phase 3 Trial." Lancet Oncol 2019.

Cita MLA

Cella, David, et al. "Patient-reported Outcomes of Patients With Advanced Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab Versus Sunitinib (CheckMate 214): A Randomised, Phase 3 Trial." Lancet Oncol 2019.